Le Couter JE - Search Results

1

Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics.

Gadkar K, Pastuskovas CV, Le Couter JE, Elliott JM, Zhang J, Lee CV, Sanowar S, Fuh G, Kim HS, Lombana TN, Spiess C, Nakamura M, Hass P, Shatz W, Meng YG, Scheer JM. Gadkar K, et al. Among authors: le couter je. Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5390-400. doi: 10.1167/iovs.15-17108. Invest Ophthalmol Vis Sci. 2015. PMID: 26275136

2

Interaction between bevacizumab and murine VEGF-A: a reassessment.

Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N. Yu L, et al. Invest Ophthalmol Vis Sci. 2008 Feb;49(2):522-7. doi: 10.1167/iovs.07-1175. Invest Ophthalmol Vis Sci. 2008. PMID: 18234994

3

Identification of an angiogenic mitogen selective for endocrine gland endothelium.

LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, Keller GA, Peale F, Gurney A, Hillan KJ, Ferrara N. LeCouter J, et al. Nature. 2001 Aug 30;412(6850):877-84. doi: 10.1038/35091000. Nature. 2001. PMID: 11528470

4

Characterization of ML-IAP protein stability and physiological role in vivo.

Varfolomeev E, Moradi E, Dynek JN, Zha J, Fedorova AV, Deshayes K, Fairbrother WJ, Newton K, Le Couter J, Vucic D. Varfolomeev E, et al. Biochem J. 2012 Nov 1;447(3):427-36. doi: 10.1042/BJ20121103. Biochem J. 2012. PMID: 22853455

5

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.

Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, Ross S, Cheng Z, Le Couter J, Plowman G, Peale F, Koch AW, Wu Y, Bagri A, Tessier-Lavigne M, Watts RJ. Pan Q, et al. Cancer Cell. 2007 Jan;11(1):53-67. doi: 10.1016/j.ccr.2006.10.018. Cancer Cell. 2007. PMID: 17222790 Free article.

6

Mechanisms of age-related macular degeneration and therapeutic opportunities.

van Lookeren Campagne M, LeCouter J, Yaspan BL, Ye W. van Lookeren Campagne M, et al. J Pathol. 2014 Jan;232(2):151-64. doi: 10.1002/path.4266. J Pathol. 2014. PMID: 24105633 Review.

7

EG-VEGF and Bv8. a novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and function.

LeCouter J, Ferrara N. LeCouter J, et al. Trends Cardiovasc Med. 2003 Oct;13(7):276-82. doi: 10.1016/s1050-1738(03)00110-5. Trends Cardiovasc Med. 2003. PMID: 14522467 Review.

8

EG-VEGF: a novel mediator of endocrine-specific angiogenesis, endothelial phenotype, and function.

Lecouter J, Lin R, Ferrara N. Lecouter J, et al. Ann N Y Acad Sci. 2004 Apr;1014:50-7. doi: 10.1196/annals.1294.005. Ann N Y Acad Sci. 2004. PMID: 15153419 Review.

9

EG-VEGF and the concept of tissue-specific angiogenic growth factors.

LeCouter J, Ferrara N. LeCouter J, et al. Semin Cell Dev Biol. 2002 Feb;13(1):3-8. doi: 10.1006/scdb.2001.0284. Semin Cell Dev Biol. 2002. PMID: 11969366 Review.

10

Characterization of endocrine gland-derived vascular endothelial growth factor signaling in adrenal cortex capillary endothelial cells.

Lin R, LeCouter J, Kowalski J, Ferrara N. Lin R, et al. J Biol Chem. 2002 Mar 8;277(10):8724-9. doi: 10.1074/jbc.M110594200. Epub 2001 Dec 20. J Biol Chem. 2002. PMID: 11751915 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters